GlassScriptPhysician profile
James Drew Norris
NPI 1639615065
$10,371.72
in general payments reported to CMS, 2019-2025
46 companies · $1,139 in 2025
The $1,139 reported for 2025 was more than what 82% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,304 · 2022: $1,494 · 2023: $1,879 · 2024: $4,556 · 2025: $1,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,574 · Honoraria: $3,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,573.70 |
| Honoraria | $3,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $3,160.36 | 2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Novo Nordisk INC | $1,122.32 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,084.96 | 2021-2025 | |
| Amgen INC. | $812.66 | 2021-2025 | Evenity, Otezla, Repatha |
| Lilly USA, LLC | $642.35 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $379.16 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $346.81 | 2022-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $283.67 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $261.66 | 2022-2025 | |
| Preventric Diagnostics, INC. | $222.85 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.71 | 2021-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $212.53 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $182.25 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $176.23 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Otsuka America Pharmaceutical, INC. | $127.23 | 2022-2025 | Rexulti |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Norris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.